RecruitingNot Applicable

Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry

United States100 participantsStarted 2023-06-06

Plain-language summary

Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Be male or female, ≥18 years of age at the time of graft placement
✓. Have a diagnosis of ESRD or renal dysfunction requiring hemodialysis
✓. Subject requires dialysis access to start or maintain dialysis treatment and placement of an AV access graft is a viable access option.
✓. Have the ability themselves, or through their legal guardian, to understand the requirements of the study, to provide written informed consent/assent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and to agree to abide by the study restrictions and return to the site for the required assessments
✓. Have provided written authorization for use and disclosure of protected health information

Exclusion criteria

✕. Be participating in a study of another investigational drug or device
✕. Have a known sensitivity to any of the processing reagents utilized in the manufacture of this product such as antibiotics (Lincomycin, Polymyxin B, Ciprofloxacin, Meropenum, Gentamicin, or Vancomycin) and processing reagents (N-lauroyl sarcosine, Denarase and glycerol/glycerin)
✕. Have a history or evidence of severe cardiac disease, myocardial infarction within 6 months, ventricular arrhythmias, or unstable angina requiring continuing treatment
✕. Have a history or evidence of severe peripheral vascular disease in the upper extremities
✕. Have the inability or be unable or unwilling to follow the study visit schedule
✕. Have the presence of any condition that, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated

What they're measuring

UltraSound evaluation of allograft functional patency.

Timeframe: 24 months

Trial details

NCT IDNCT05880537

SponsorLifeNet Health

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-12-15

Contact for this trial

Kimberly Dorsch

757-609-4378 kimberly_dorsch@lifenethealth.org

View on ClinicalTrials.gov More End-Stage Renal Disease trials